digestive system diseases
Conditions
Interventions
Control group (Group S1):Improved up-and-down sequential method: initial Sufentanil dose 0.1 µg/kg with a ratio of 1:1.1
Experimental group:Group O2: Ciprofol + Oliceridine ED95
Experimental group (Group O1):Improved up-and-down sequential method, initial dose of Oliceridine 10 µg/kg at a 1:1.2 ratio
Control group:Group S2: Ciprofol + Sufentanil ED95
Sponsors
Liuzhou people's hospital
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-64 years; 2. BMI 18.5-27.9 kg/m^2; 3. ASA physical status I or II.
Exclusion criteria
Exclusion criteria: 1.Allergy to study drugs or contraindications to anesthesia; ?Severe cardiac or pulmonary diseases; 2.Severe cardiac or pulmonary diseases; 3.Neuropsychiatric disorders; 4.Anticipated difficult airway; 5.Severe anemia or thrombocytopenia; 6.History of analgesic or alcohol abuse; 7.Acute upper respiratory tract infection or asthma attack within the past 2 weeks;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation success rate;Incidence of subclinical respiratory depression; | — |
Countries
China
Contacts
Public ContactLiang Dong
Liuzhou people's hospital
Outcome results
None listed